Tianjin Medson Pharmaceutical Technology Co., Ltd., established in 2011, is a research-oriented enterprise integrating scientific research, production, and trade in pharmaceutical active pharmaceutical ingredients (APIs), intermediates, and various fine chemicals. The company currently has departments for synthesis, analysis, pilot research, and production. Relying on Tianjin University, the company has established a joint laboratory there. With a research team led by professors and pharmaceutical doctors, it has independently or collaboratively developed multiple series of pharmaceutical APIs and intermediate products. Order sizes range from grams and kilograms to tons, meeting the needs of small-scale R&D trials, pilot experiments, and large-scale production. The company adheres to the goals of resource sharing, complementary advantages, and mutual benefit, upholding principles of honesty and fairness. It continuously meets the growing market demands with high-quality, diverse product series and efficient, excellent services. The main product series provided by Tianjin Medson Pharmaceutical Technology Co., Ltd. include: API series, including APIs, intermediates, and impurities such as Roflumilast, Retigabine, Ambrisentan, Parecoxib Sodium, Laquinimod, Pemetrexed, Betrixaban, etc.; piperazine and homopiperazine derivative series; piperidinone derivative series; carboxyfluorescein series, among others. Professional project managers, R&D personnel, and production managers can customize the production of fine chemical products from grams and kilograms to tons according to customer requirements.